A 3-STEP APPROACH COMBINING BAYESIAN REGRESSION AND NONMEM POPULATION ANALYSIS - APPLICATION TO MIDAZOLAM

被引:144
作者
MAITRE, PO
BUHRER, M
THOMSON, D
STANSKI, DR
机构
[1] UNIV BERN,INSELSPITAL,DEPT ANESTHESIOL & INTENS CARE,CH-3010 BERN,SWITZERLAND
[2] UNIV BASEL,DEPT ANESTHESIOL,CH-4051 BASEL,SWITZERLAND
[3] VET ADM MED CTR,PALO ALTO,CA 94304
[4] STANFORD UNIV,DEPT ANESTHESIOL,STANFORD,CA 94305
来源
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS | 1991年 / 19卷 / 04期
关键词
MIDAZOLAM KINETICS; POPULATION ANALYSIS;
D O I
10.1007/BF01061662
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
NONMEM, the only available supported program for population pharmacokinetic analysis, does not provide the analyst with individual subject parameter estimates. As a result, the relationship between pharmacokinetic parameters and demographic factors such as age, gender, and body weight cannot be sought by plotting demographic factors vs. kinetic parameters. To overcome this problem, we devised a three-step approach. In step 1, an initial NONMEM analysis provides the population pharmacokinetic parameters without taking into account the demographic factors. Step 2 consists of individual bayesian regressions using the measured drug concentrations for each subject and the population pharmacokinetic parameters obtained in step 1. The bayesian parameter estimates of the individual subject can be plotted against the demographic factors of interest. From the scatter plots, it can be seen which are the demographic factors that appear to affect the pharmacokinetic parameters. In step 3, the NONMEM analysis is resumed, and the demographic factors found in step 2 are entered into the NONMEM regression model in a stepwise manner. This method was used to analyze the pharmacokinetics of midazolam in 64 subjects from 714 plasma concentrations and 11 demographic factors. CL (elimination clearance) and V1 were found to be a function of body weight. Age and liver disease were found to decrease CL. Of the 11 demographic factors recorded for each patient, none was found to influence V(ss) or intercompartmental clearance.
引用
收藏
页码:377 / 384
页数:8
相关论文
共 5 条
  • [1] Beal SL, NONMEM USERS GUIDE
  • [2] EFFECT OF AGE, GENDER, AND OBESITY ON MIDAZOLAM KINETICS
    GREENBLATT, DJ
    ABERNETHY, DR
    LOCNISKAR, A
    HARMATZ, JS
    LIMJUCO, RA
    SHADER, RI
    [J]. ANESTHESIOLOGY, 1984, 61 (01) : 27 - 35
  • [3] PHARMACOKINETICS OF MIDAZOLAM IN PATIENTS RECOVERING FROM CARDIAC-SURGERY
    MAITRE, PO
    FUNK, B
    CREVOISIER, C
    HA, HR
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 37 (02) : 161 - 166
  • [4] ASA PHYSICAL STATUS CLASSIFICATIONS - STUDY OF CONSISTENCY OF RATINGS
    OWENS, WD
    FELTS, JA
    SPITZNAGEL, EL
    [J]. ANESTHESIOLOGY, 1978, 49 (04) : 239 - 243
  • [5] ESTIMATION OF POPULATION CHARACTERISTICS OF PHARMACOKINETIC PARAMETERS FROM ROUTINE CLINICAL DATA
    SHEINER, LB
    ROSENBERG, B
    MARATHE, VV
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1977, 5 (05): : 445 - 479